Allogene Therapeutics, Inc. (ALLO)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
2.02 USD
-0.07
(-3.349%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.01 -0.01 (-0.007%) ⇩ (Aug. 28, 2026, 7:36 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:48 a.m. EDT
The investment case here is fundamentally broken. This biotech stock has suffered a catastrophic multi-year decline, dropping nearly 96% over the last six years with five consecutive years of negative returns. Despite a 'strong buy' analyst recommendation driven by potential FDA milestones and a massive public offering, the market has priced in severe distress, reflected in a negative forward P/E and a balance sheet burning through cash with no revenue. The recent price action shows a fragile, sideways bounce rather than a recovery trend, while options flow confirms deep skepticism with heavy put buying. The statistical forecast models also lean slightly negative, aligning with the broader picture of a company struggling to survive rather than thrive. Until there is undeniable proof of commercial product success and a path to profitability, this remains a high-risk speculative vehicle with no margin of safety. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.068481 |
| AutoARIMA | 0.111775 |
| AutoETS | 0.111778 |
| MSTL | 0.118860 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.471 |
| Excess Kurtosis | -0.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 18.114 |
| Revenue per Share | 0.018 |
| Market Cap | 697,891,584 |
| Forward P/E | -2.88 |
| Beta | 0.47 |
| Website | https://allogene.com |
As of Aug. 22, 2026, 2:48 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly in the February 2027 expiration where put volume significantly exceeds open interest at key strikes. While there is some call activity at distant strikes (5.0), the immediate term shows a distinct lack of bullish conviction, with ATM call volume being negligible compared to put flow.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.80357146 |
| Address1 | 210 East Grand Avenue |
| All Time High | 55.0 |
| All Time Low | 0.86 |
| Ask | 4.25 |
| Ask Size | 1 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 4,944,100 |
| Average Daily Volume3 Month | 7,660,487 |
| Average Volume | 7,660,487 |
| Average Volume10Days | 4,944,100 |
| Beta | 0.466 |
| Bid | 2.03 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 1.263 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.02 |
| Current Ratio | 10.716 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.09 |
| Day Low | 2.01 |
| Debt To Equity | 18.114 |
| Display Name | Allogene Therapeutics |
| Earnings Call Timestamp End | 1,786,568,400 |
| Earnings Call Timestamp Start | 1,786,568,400 |
| Earnings Timestamp | 1,786,564,800 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -168,648,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.634 |
| Enterprise To Revenue | 95.754 |
| Enterprise Value | 444,296,576 |
| Eps Current Year | -0.58634 |
| Eps Forward | -0.70221 |
| Eps Trailing Twelve Months | -0.63 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.992 |
| Fifty Day Average Change | 0.027999997 |
| Fifty Day Average Change Percent | 0.014056223 |
| Fifty Two Week Change Percent | 80.35715 |
| Fifty Two Week High | 4.46 |
| Fifty Two Week High Change | -2.44 |
| Fifty Two Week High Change Percent | -0.5470852 |
| Fifty Two Week Low | 1.04 |
| Fifty Two Week Low Change | 0.98 |
| Fifty Two Week Low Change Percent | 0.9423078 |
| Fifty Two Week Range | 1.04 - 4.46 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,539,264,600,000 |
| Float Shares | 262,414,144 |
| Forward Eps | -0.70221 |
| Forward P E | -2.8766322 |
| Free Cashflow | -63,461,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 150 |
| Fullday Change | -0.0699999 |
| Fullday Change Percent | -3.34928 |
| Fullday Price | 2.0131 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -117,880,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11033 |
| Held Percent Institutions | 0.87316 |
| Implied Shares Outstanding | 345,490,881 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California. |
| Long Name | Allogene Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 697,891,584 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_558022022 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -165,494,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 723,803,395 |
| Number Of Analyst Opinions | 9 |
| Open | 2.07 |
| Operating Cashflow | -102,196,000 |
| Operating Margins | -10.11207 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 457 2700 |
| Post Market Change | -0.006900072 |
| Post Market Change Percent | -0.34158772 |
| Post Market Price | 2.0131 |
| Post Market Time | 1,787,960,182 |
| Previous Close | 2.09 |
| Price Eps Current Year | -3.4451 |
| Price Hint | 4 |
| Price To Book | 1.5993665 |
| Price To Sales Trailing12 Months | 150.40767 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.553 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.41667 |
| Region | US |
| Regular Market Change | -0.0699999 |
| Regular Market Change Percent | -3.34928 |
| Regular Market Day High | 2.09 |
| Regular Market Day Low | 2.0 |
| Regular Market Day Range | 2.0 - 2.09 |
| Regular Market Open | 2.07 |
| Regular Market Previous Close | 2.09 |
| Regular Market Price | 2.02 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 3,823,008 |
| Return On Assets | -0.22083001 |
| Return On Equity | -0.42394 |
| Revenue Per Share | 0.018 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 345,490,881 |
| Shares Percent Shares Out | 0.1706 |
| Shares Short | 58,945,687 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 59,712,398 |
| Short Name | Allogene Therapeutics, Inc. |
| Short Percent Of Float | 0.18879999 |
| Short Ratio | 10.07 |
| Source Interval | 15 |
| State | CA |
| Symbol | ALLO |
| Target High Price | 14.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 9.0 |
| Target Median Price | 9.0 |
| Total Cash | 332,604,000 |
| Total Cash Per Share | 0.963 |
| Total Debt | 79,009,000 |
| Total Revenue | 4,640,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.63 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.94765 |
| Two Hundred Day Average Change | 0.072350025 |
| Two Hundred Day Average Change Percent | 0.037147347 |
| Type Disp | Equity |
| Volume | 3,823,008 |
| Website | https://allogene.com |
| Zip | 94,080 |